Abstract:As one of the most common breast cancer subtypes, luminal A breast cancer is sensitive to endocrine-based therapy and insensitive to chemotherapy. Patients with luminal A subtype of breast cancer have a relatively good prognosis compared with that of patients with other subtypes of breast cancer. However, with the increased incidence in endocrine resistance and severe side effects, simple endocrine therapy has become unsuitable for the treatment of luminal A breast cancer. Therefore, identifying novel therapeutic targets for luminal A breast cancer may accelerate the development of an effective therapeutic strategy. The bioinformatical analysis of the current study, which included KEGG and GO analyses of the GSE20437 dataset containing 24 healthy and 18 breast cancer tissue samples, identified key target genes associated with breast cancer. Moreover, survival analysis results revealed that a low expression of BTG2 was significantly associated with the low survival rate of patients with breast cancer, indicated that B-cell translocation gene 2 (BTG2) may be a potential target in breast cancer. However, BTG2 may be cancer type-dependent, as overexpression of BTG2 has been demonstrated to suppress the proliferation of pancreatic and lung cancer cells, but promote the proliferation of bladder cancer cells. Since the association between BTG2 and luminal A-subtype breast cancer remains unclear, it is important to understand the biological function of BTG2 in luminal A breast cancer. Based on the expression levels of estrogen receptor, progesterone receptor and human epidermal growth factor receptor, MCF-7 cells were selected in the present study as a luminal A breast cancer cell type. MTT, Transwell invasion and wound healing assays revealed that overexpression of BTG2 suppressed the levels of MCF-7 cell proliferation, migration and invasion. In addition, the downregulation of BTG2 at the mRNA and protein level was also confirmed in luminal A breast tumor tissue, which was consistent with the results in vitro. These results indicated that BTG2 may act as an effective target for the treatment of luminal A breast cancer.

BTG2 Suppresses the Growth and Metastasis of Cervical Squamous Cell Carcinoma

DSG2 and C-Myc Interact to Regulate the Expression of ADAM17 and Promote the Development of Cervical Cancer

BTG2 Is Down-Regulated and Inhibits Cancer Stem Cell-Like Features of Side Population Cells in Hepatocellular Carcinoma

BTG2 Inhibits the Proliferation, Invasion, and Apoptosis of MDA-MB-231 Triple-Negative Breast Cancer Cells

BTG2 overexpression increases the radiosensitivity of breast cancer cells in vitro and in vivo.

Inhibitory Effects of B‑cell Translocation Gene 2 on Skin Cancer Cells Via the Wnt/β‑catenin Signaling Pathway.

BTG2 As a Tumor Target for the Treatment of Luminal A Breast Cancer

Expression of B-cell Translocation Gene 2 is Associated with Favorable Prognosis in Hepatocellular Carcinoma Patients and Sensitizes Irradiation-Induced Hepatocellular Carcinoma Cell Apoptosis in Vitro and in Nude Mice.

BTG2 Inhibits the Proliferation and Metastasis of Osteosarcoma Cells by Suppressing the PI3K/AKT Pathway.

Transcriptomic Analyses Reveal B-Cell Translocation Gene 2 as a Potential Therapeutic Target in Ovarian Cancer

BTG2 suppresses renal cell carcinoma progression through N6-methyladenosine

Effect of B-cell Translocation Gene 2 Alteration on Radiosensitivity of Cancer Cells

B-Cell Translocation Gene 2 Upregulation is Associated with Favorable Prognosis in Lung Adenocarcinoma and Prolonged Patient Survival

Research Progress of BTG2 As a Tumor Prognostic Factor

B‑cell translocation 1 gene inhibits cellular metastasis‑associated behavior in breast cancer.

Effects of BTG2 Overexpression on the Radiosensitivity of Human Breast Cancer T-47D Cells

Telocinobufagin, a PLK1 suppressor that inhibits tumor growth and metastasis by modulating CDC25c and CTCF in HNSCC cells

P3.16-01 A Multi-Omic Study Reveals BTG2 As a Reliable Prognostic Marker for Early-Stage Non-Small Cell Lung Cancer

KBTBD2 promotes proliferation and migration of gastric cancer via activating EGFR signaling pathway

Tpx2 Regulates Tumor Growth in Human Cervical Carcinoma Cells

Long non-coding RNA CASC2 targeting miR-18a suppresses glioblastoma cell growth, metastasis and EMT in vitro and in vivo